36.85

6.41% +2.22

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is currently priced at $36.85, with a 24-hour trading volume of 682.85K. It has seen a +6.41% increased in the last 24 hours and a +2.70% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $33.76 pivot point. If it approaches the $38.11 resistance level, significant changes may occur.

Previous Close:

$34.63

Open:

$35.75

24h Volume:

682.85K

Market Cap:

$1.39B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-10.90

EPS:

-3.38

Net Cash Flow:

$-123.00M

1W Performance:

+15.01%

1M Performance:

+2.70%

6M Performance:

+130.31%

1Y Performance:

+143.88%

1D Range:

$35.51

$37.14

52W Range:

$12.57

$40.40

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

949-409-9820

Address

15440 Laguna Canyon Road, Suite 160, Irvine

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

TARS's Discussions on Twitter

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

GlobeNewswire Inc.

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

GlobeNewswire Inc.

Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know

Zacks Investment Research

Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why

Zacks Investment Research

How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%

Zacks Investment Research

Tarsus to Participate at Upcoming Investor Conferences

GlobeNewswire Inc.

Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data

Tarsus Pharmaceuticals Inc (TARS) Revenue 2024

TARS reported a revenue (TTM) of $17.39 million for the quarter ending June 30, 2022.

Tarsus Pharmaceuticals Inc (TARS) Net Income 2024

TARS net income (TTM) was -$135.89 million for the quarter ending December 31, 2023, a -118.86% decrease year-over-year.

Tarsus Pharmaceuticals Inc (TARS) Cash Flow 2024

TARS recorded a free cash flow (TTM) of -$123.00 million for the quarter ending December 31, 2023, a -148.29% decrease year-over-year.

Tarsus Pharmaceuticals Inc (TARS) Earnings per Share 2024

TARS earnings per share (TTM) was -$4.64 for the quarter ending December 31, 2023, a -81.65% decline year-over-year.

Tarsus Pharmaceuticals Inc Stock (TARS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Neervannan Seshadri	Chief Operating Officer	Mar 18 '24	Sale	30.60	4,879	149,297	64,767
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '24	Sale	30.60	4,766	145,840	54,075
Wahl Bryan	General Counsel	Mar 18 '24	Sale	30.60	4,436	135,742	40,951
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '24	Sale	30.60	4,314	132,008	34,181
Azamian Bobak R.	President/CEO and Board Chair	Dec 27 '23	Sale	20.22	8,000	161,760	830,106
Azamian Bobak R.	President/CEO and Board Chair	Dec 20 '23	Sale	20.27	40,000	810,623	838,106
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	20.00	2,252	45,040	2,251
Goldberg Andrew D.	Director	Dec 15 '23	Buy	18.96	1,000	18,960	3,000
Wahl Bryan	General Counsel	Nov 30 '23	Sale	16.31	8,356	136,286	31,966
Whitfield Dianne C.	Chief Human Resources Officer	Nov 30 '23	Sale	16.31	8,355	136,270	26,784

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.